Cofactor uses RNA and Predictive Immune Modeling to build better biomarkers and improve patient outcomes. Led by Jarret Glasscock and a group of expert human genome scientists,Cofactor has built a new category of diagnostic technology powered by unique and powerful RNA data models built on terabytes of data.
Cofactor Genomics is a Y Combinator company in the Summer 2015 batch. Its directory entry describes it as: Cofactor closes the precision medicine gap with predictive diagnostics. The founders listed are Dave Messina (Founder/COO), Jarret Glasscock (Founder/CTO) (Y Combinator directory entry, June 4, 2015).
Sell to companies like Cofactor Genomics? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New accelerator entry · 2015-06-04 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Cofactor Genomics.
Free to see. No signup.
More on Cofactor Genomics and the records around it.
Same batch, Healthcare first.
Get an email when Cofactor Genomics changes status, grows its team or files a funding notice. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Cofactor Genomics raises, hires or launches. No email unless you switch it on.
Watch Cofactor Genomics →Get the full cited report on Cofactor Genomics
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Cofactor Genomics: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Cofactor uses RNA and Predictive Immune Modeling to build better biomarkers and improve patient outcomes. Led by Jarret Glasscock and a group of expert human genome scientists,Cofactor has built a new category of diagnostic technology powered by unique and powerful RNA data models built on terabytes of data. The team recently had their technology validation peer-reviewed by the organizations that set standards for diagnostic technology (CAP, AMP) and is publishing in the Journal of Molecular Diagnostics. In addition, the team made news when Cancer Physicians who sit on the committee for patient treatment guidelines (NCCN) presented a clinical study using Cofactor’s technology showing superiority in predicting the patients who will respond to immunotherapy. This initial application is an acute problem recognized widely in the rapidly developing immunotherapy industry and represents north of a billion dollar TAM. After a number of recent key milestones, the team is taking the technology more broadly to 50% of cancers diagnosed in the US. Current investors include Menlo Ventures, DCVC, and Ascension Ventures (this last investor representing the funding arm for 13 National U.S. Healthcare Systems).
Founders, titles and bios as the company published them. Photographs are our own copies of the ones on that record, so they do not break when the original link expires.
No investor is drawn from a Form D — the form states how many invested and never who. The one investor on this graph is named because a batch has exactly one.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Cofactor Genomics: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cofactor Genomics covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Cofactor GenomicsYou get an alert in MentionFox the next time this company shows up.
If you're behind Cofactor Genomics: acceptance into a YC batch is one of the few weeks a young company gets looked up by people who matter — investors, other founders, press. FoxPlug turns the commits, deploys, and releases you're already making into that story automatically, so anyone who looks finds something current. GetFoxChat puts a guide on your own site so the people YC's own page just sent you don't read one line and leave.
Sourced from the company's Y Combinator directory entry.
Each opens in a new tab, filled in for Cofactor Genomics. With no account yet, you sign up free and land on the result.
Healthcare and health tech startups Medical device and diagnostics startups
Share the news. Sharing needs no account.
https://mentionfox.com/funding/yc-cofactor-genomics